Enlivex Therapeutics Stock Quote ENLV - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

1.30

Bid

1.27

Ask

1.29

Volume

264

0.00 Day's Range 0.00

1.15 52 Week Range 4.59

Market Cap

23.946M

Previous Close

1.30

Open

Last Trade

1.29

Last Trade Time

06:47:06

Financial Volume

VWAP

Average Volume (3m)

168,396

Shares Outstanding

18,420,000

Dividend Yield

PE Ratio

-0.77

Earnings Per Share (EPS)

-1.69

Revenue

Net Profit

-31.06M

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threate... Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.enlivex.com

Headquarters

Ness Ziona, Center, Isr

Founded

1970

Enlivex Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ENLV. The last closing price for Enlivex Therapeutics was $1.30. Over the last year, Enlivex Therapeutics shares have traded in a share price range of $ 1.15 to $ 4.59.

Enlivex Therapeutics currently has 18,420,000 shares outstanding. The market capitalization of Enlivex Therapeutics is $23.95 million. Enlivex Therapeutics has a price to earnings ratio (PE ratio) of -0.77.

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Nes-Ziona, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Second study of Allocetra in knee osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage osteoarthritis, that is continuing to enroll patients Nes-Ziona, Israel, Jan...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-2.81	-68.3698296837	4.11	4.21	1.15	979395	1.7835585	CS
4	-2.81	-68.3698296837	4.11	4.59	1.15	349080	2.34894103	CS
12	-1.4	-51.8518518519	2.7	4.59	1.15	168396	2.66335228	CS
26	-0.12	-8.45070422535	1.42	4.59	1.15	120463	2.63176729	CS
52	-1.6	-55.1724137931	2.9	4.59	1.15	72204	2.58743656	CS
156	-9.83	-88.3198562444	11.13	13.95	1.15	85869	6.91741446	CS
260	-8.05	-86.0962566845	9.35	44.9	1.15	157621	9.91991797	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DYNTDynatronics Corp	$ 0.6839 (84.64%)	2.33M
DFLIDragonfly Energy Holdings Corporation	$ 0.7009 (55.76%)	3.31M
MCBCMacatawa Bank Corporation	$ 13.79 (38.87%)	24.97k
WISAWiSA Technologies Inc	$ 2.31 (32.00%)	1.77M
MOBMobilicom Ltd	$ 1.53 (22.40%)	2.33M
ALPPAlpine 4 Holdings Inc	$ 0.5111 (-30.93%)	1
RVYLRYVYL Inc	$ 1.45 (-29.65%)	18.06k
AIHAesthetic Medical International Holdings Group Ltd	$ 0.3029 (-23.34%)	1
INOInovio Pharmaceuticals Inc New	$ 8.54 (-22.29%)	2.1k
SJScienjoy Holding Corporation	$ 0.85 (-15.42%)	33
KXINKaixin Holdings	$ 0.1719 (14.60%)	9.62M
DFLIDragonfly Energy Holdings Corporation	$ 0.7009 (55.76%)	3.31M
SPCBSuperCom Ltd	$ 0.4565 (14.01%)	3.15M
DYNTDynatronics Corp	$ 0.6839 (84.64%)	2.33M
MOBMobilicom Ltd	$ 1.53 (22.40%)	2.33M